Darunavir (Prezista) for HIV Infection
Darunavir (Prezista - Tibotec), a new protease inhibitor, has received accelerated approval from the FDA for use in combination therapy of human-immunodeficiency virus (HIV) infection in previously treated adults. It is coadministered with low-dose ritonavir (Norvir), which increases its bioavailability....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Darunavir (Prezista) for HIV Infection
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1243
Article Code: 1243b
Date: September 11, 2006
Volume: 48
Pages: 74-75
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1243
Article Code: 1243b
Date: September 11, 2006
Volume: 48
Pages: 74-75
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)